@drchrisraynor
1 post audited · 1 claims analysed
Science evidence grade
Based on 1 claim across 1 audit
1
Supported
100%
0
Overstated
0%
0
Misleading
0%
0
No Evidence
0%
Share this evidence grade
Claim-level evidence grades — not a character judgment. Methodology · Right of reply · Leaderboards
What @drchrisraynor claims actually are
We separate claims into three buckets: backed by evidence, factually incorrect, and grey — like animal-only findings sold as human fact (e.g. BPC-157 “fixes Achilles” from rat studies).
Evidence-based
100%
1 claim
Claims that align with published human or clinical evidence at the stated strength.
Ex: “Semaglutide can reduce body weight in adults with obesity” — supported by large RCTs.
Factually incorrect
0%
0 claims
Claims that conflict with the evidence, invent certainty, or omit critical safety/context in a misleading way.
Ex: “Peptides have no side effects” — contradicts known adverse-event profiles.
Grey / overstated
0%
0 claims
Plausible direction but wrong certainty — animal-only data sold as human fact, dose/effect overstated, or no adequate published support yet.
Ex: “BPC-157 fixes Achilles tears” — often rests on rodent tendon models, not proven human Achilles repair trials.
Evidence mix
Share of audited claims in each bucket
Verdict detail
Grey splits into overstated (wrong certainty) vs no published support
Claims over time
Stacked by bucket as audits land — plus the running evidence grade
Gold line = running science evidence grade (Supported + ½ Overstated ÷ total claims).
Audit history(1 post)
“Retatrutide: the new triple G peptide is blowing up in fitness circles, but here’s what most aren’t telling you. It’s still investigational, not approved. Buying online? You’re skipping real safety systems—risk skyrockets. Bottom line: Don’t gamble with your health on gray market injectables. Get medical supervision, protect your muscle, and build real habits. #Retatrutide #tripleagonist #peptides #weightloss #leanmuscle”
The claim that retatrutide is a triple G peptide is robustly supported by peer-reviewed literature. The 2024 Melson et al. review in International Journal of Obesity explicitly confirms retatrutide's mechanism as a GLP-1/GIP/glucagon triple receptor agonist and documents its progression to Phase III obesity trials. This is not speculative or marketing language—it is the consensus characterization in published clinical reviews. The 'triple G' terminology accurately reflects the scientific designation of its receptor profile.
Audit another post from @drchrisraynor
Paste their social post link to add a new audit